PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 77 points (0.5%) at 16,913 as of Friday, June 6, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,319 issues advancing vs. 667 declining with 134 unchanged.

The Drugs industry currently sits up 1.5% versus the S&P 500, which is up 0.4%. On the negative front, top decliners within the industry include Biomarin Pharmaceutical ( BMRN), down 2.8%, Biogen Idec ( BIIB), down 1.2%, Gilead ( GILD), down 0.8% and Valeant Pharmaceuticals International ( VRX), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Pharmacyclics ( PCYC) is one of the companies pushing the Drugs industry lower today. As of noon trading, Pharmacyclics is down $2.52 (-2.7%) to $91.54 on average volume. Thus far, 668,646 shares of Pharmacyclics exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $91.45-$94.71 after having opened the day at $94.36 as compared to the previous trading day's close of $94.06.

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. Pharmacyclics has a market cap of $7.1 billion and is part of the health care sector. Shares are down 11.1% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Pharmacyclics a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Pharmacyclics as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including poor profit margins, relatively poor performance when compared with the S&P 500 during the past year and feeble growth in the company's earnings per share. Get the full Pharmacyclics Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015